DOCSLIB.ORG

Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas Published OnlineFirst September 7, 2016; DOI: 10.1158/0008-5472.CAN-15-2507 Cancer Tumor and Stem Cell Biology Research Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas Kai-Oliver Henrich1, Sebastian Bender2, Maral Saadati3, Daniel Dreidax1, Moritz Gartlgruber1, Chunxuan Shao4, Carl Herrmann5, Manuel Wiesenfarth3, Martha Parzonka1, Lea Wehrmann1, Matthias Fischer6, David J. Duffy7, Emma Bell8, Alica Torkov1, Peter Schmezer9, Christoph Plass9, Thomas Hofer€ 4, Axel Benner3, Stefan M. Pfister2, and Frank Westermann1 Abstract The broad clinical spectrum of neuroblastoma ranges from MYCN. Transcriptome integration and histone modification– spontaneous regression to rapid progression despite intensive based definition of enhancer elements revealed intragenic multimodal therapy. This diversity is not fully explained by enhancer methylation as a mechanism for high-risk–associated known genetic aberrations, suggesting the possibility of epige- transcriptional deregulation. Furthermore, in high-risk neuro- netic involvement in pathogenesis. In pursuit of this hypothesis, blastomas, we obtained evidence for cooperation between we took an integrative approach to analyze the methylomes, PRC2 activity and DNA methylation in blocking tumor-sup- transcriptomes, and copy number variations in 105 cases of pressive differentiation programs. Notably, these programs neuroblastoma, complemented by primary tumor- and cell could be re-activated by combination treatments, which tar- line–derived global histone modification analyses and epigenetic geted both PRC2 and DNA methylation. Overall, our results drug treatment in vitro. We found that DNA methylation pat- illuminate how epigenetic deregulation contributes to neuro- terns identify divergent patient subgroups with respect to blastoma pathogenesis, with novel implications for its diagnosis survival and clinicobiologic variables, including amplified and therapy. Cancer Res; 76(18); 1–15. Ó2016 AACR. Introduction DNA methylation, an epigenetic modification via methylation of cytosin carbon 5, is a major mechanism in cell differentiation Neuroblastoma originates from precursor cells of the sympa- and neoplastic transformation. Promoter-associated CpG islands thetic nervous system. It is the most frequent solid tumor of early have been identified as frequent targets of transcriptionally relevant childhood with a remarkable variation in clinical and biological methylation events. Accumulating evidence, however, suggests that behavior ranging from spontaneous regression to rapid progres- nonpromoter methylation may be also actively involved in gene sion in spite of intensive multimodal chemotherapy. The molec- regulatory processes and is an abundant phenomenon among ular basis of neuroblastoma pathogenesis is still poorly under- somatically acquired methylation changes in human cancer stood. Genetic alterations seen in high-risk tumors include ampli- (4, 5). In neuroblastoma, candidate-based approaches revealed fication of the proto-oncogene MYCN, activation of the ALK gene, methylation of several genes including CASP8 (6), which plays an heterozygous deletions of 1p or 11q and gain of 17q. However, important role in the TNF-related apoptosis pathway. Global the molecular etiology of a substantial portion of aggressive approaches based on epigenetic drug-induced re-expression anal- neuroblastomas remains largely enigmatic. Recurrent somatic yses and/or affinity-based capture methods in neuroblastoma cell mutations are rare (1–3), suggesting that epigenetic mechanisms lines revealed further potential mechanisms and targets of DNA may drive neuroblastoma development and progression. methylation in neuroblastoma (7, 8). Further reports suggested the 1Neuroblastoma Genomics B087, German Cancer Research Center, Hei- Note: Supplementary data for this article are available at Cancer Research 2 delberg, Germany. Division of Pediatric Neurooncology, German Can- Online (http://cancerres.aacrjournals.org/). cer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany & Department of Pediatric Oncology, Hematology and Immu- K.-O. Henrich, S. Bender, and M. Saadati contributed equally as co-first authors to nology, Heidelberg University Hospital, Germany. 3Division of Biostatis- this article. tics, German Cancer Research Center, Heidelberg, Germany. 4Division of fi Theoretical Systems Biology, German Cancer Research Center, Heidel- A. Benner, S.M. P ster, and F. Westermann contributed equally as co-senior berg, Germany. 5Division of Theoretical Bioinformatics, German Cancer authors to this article. Research Center, Institute of Pharmacy and Molecular Biotechnology, Corresponding Authors: Kai-Oliver Henrich, German Cancer Research Center Bioquant, University of Heidelberg, Germany. 6Department of Pediatric (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany. Phone: 4962- Oncology, University Children's Hospital, and Center for Molecular Med- icine Cologne (CMMC), University of Cologne, Cologne, Germany. 7Sys- 2142-3279; Fax: 4962-2142-3277; E-mail: k.henrich@dkfz; and Frank Wester- tems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland. mann, [email protected] 8 Department of Pathology, University of Cambridge, Cambridge, United doi: 10.1158/0008-5472.CAN-15-2507 Kingdom. 9Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany. Ó2016 American Association for Cancer Research. www.aacrjournals.org OF1 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst September 7, 2016; DOI: 10.1158/0008-5472.CAN-15-2507 Henrich et al. presence of a CpG island methylator phenotype (CIMP), defined MYCN levels, stable neuroblastoma cell models were used as widespread simultaneous CpG island methylation, which is where MYCN can be either up- or downregulated upon addition significantly associated with poor outcome (9, 10). Genome-wide of tetracycline [SH-SY5Y-MYCN and IMR5-75-shMYCN (small DNA methylation analyses in primary neuroblastomas using hairpin RNA targeting MYCN), respectively; refs. 16, 17]. IMR5- methylated DNA immunoprecipitation (MeDIP) or DNA meth- 75-shMYCN with and without MYCN knockdown (ÆTet) were ylation arrays identified methylation events representing new synchronized via thymidine (2 mmol/L) block for 18 hours candidate epigenetic biomarkers (11–14). An integrated approach, before release by wash out. combining methylome, transcriptome, and genome data from a large cohort of primary neuroblastomas with chromatin modifi- Array-based gene expression and DNA methylation profiling cation analyses has, however, not yet been applied. Expression profiles were generated using customized 4 Â 44 Here, we analyzed DNA methylation in 105 neuroblastomas K oligonucleotide microarrays (Agilent Technologies) and using the Illumina 450k methylation array, which covers pro- genome-wide DNA methylation was assessed using Infinium moter and gene body sites of 99% of Refseq-annotated genes. HumanMethylation450 (450k) BeadChips (Illumina). See These data were complemented by expression profiles and copy Supplementary Materials and Methods for details. number information from the same tumors and combined with Genomic annotation of CpGs was done using the assign- primary neuroblastoma- and cell line–derived global histone GenomeAnnotation program of the HOMER tool suite (http:// modification data. We identified functional programs targeted homer.salk.edu/homer). GpGs with gene context annotations by epigenetic mechanisms in high-risk neuroblastomas and pro- "EXON", "INTRON", "3UTR" and "TTS" (transcription termina- vide evidence for methylation of intragenic enhancers being a tion site) were defined as intragenic (gene body), whereas CpGs mechanism of high-risk–associated transcriptional dysregulation. with annotations "PROMOTER-TSS" and "5UTR" were defined as Furthermore, our data suggest an active contribution of PRC2 50-associated. For association of DNA methylation and gene components to the downregulation of tumor-suppressive genes expression data, only CpGs with gene context annotation were that are hypermethylated in high-risk patients. In line with this, a considered. MassARRAY analysis (Sequenom) at two selected combination of drugs targeting the repressive effect of both DNA CpGs within CDKN2D revealed strong correlation with methyl- methylation and PRC2 efficiently reinduced programs epigenet- ation levels assessed by 450k arrays [Pearson correlation coeffi- ically impaired in high-risk disease. Our results provide funda- cients: 0.85 (95% confidence interval (CI), 0.79–0.90) and 0.89 mental new insights into epigenetic deregulation of aggressive (95% CI, 0.84–0.92; ref. 18]. neuroblastoma and may open new diagnostic and therapeutic avenues for children with high-risk disease. Detection of copy number alterations Copy number alterations were assessed in the 450k Infinium Patients and Methods array data using a previously described custom approach inte- Patients grating both methylated and unmethylated signals (19). Result- fi All patients were enrolled in the German Neuroblastoma Trial ing pro les were manually curated and overall genomic patterns fi (NB97þNB2004) and diagnosed between 1998 and 2011. Treat- used for patient risk strati cation according to Janoueix-Lerosey ment was according to the trial guidelines. Informed consent was and colleagues (20). obtained from the patients' parents and
Load more

Recommended publications
  • A Genetic Screening Identifies a Component of the SWI/SNF Complex, Arid1b As a Senescence Regulator
    A genetic screening identifies a component of the SWI/SNF complex, Arid1b as a senescence regulator Sadaf Khan A thesis submitted to Imperial College London for the degree of Doctor in Philosophy MRC Clinical Sciences Centre Imperial College London, School of Medicine July 2013 Statement of originality All experiments included in this thesis were performed by myself unless otherwise stated. Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives license. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the license terms of this work. 2 Abstract Senescence is an important tumour suppressor mechanism, which prevents the proliferation of stressed or damaged cells. The use of RNA interference to identify genes with a role in senescence is an important tool in the discovery of novel cancer genes. In this work, a protocol was established for conducting bypass of senescence screenings, using shRNA libraries together with next-generation sequencing. Using this approach, the SWI/SNF subunit Arid1b was identified as a regulator of cellular lifespan in MEFs. SWI/SNF is a large multi-subunit complex that remodels chromatin. Mutations in SWI/SNF proteins are frequently associated with cancer, suggesting that SWI/SNF components are tumour suppressors. Here the role of ARID1B during senescence was investigated. Depletion of ARID1B extends the proliferative capacity of primary mouse and human fibroblasts.
    [Show full text]
  • In Vivo Studies Using the Classical Mouse Diversity Panel
    The Mouse Diversity Panel Predicts Clinical Drug Toxicity Risk Where Classical Models Fail Alison Harrill, Ph.D The Hamner-UNC Institute for Drug Safety Sciences 0 The Importance of Predicting Clinical Adverse Drug Reactions (ADR) Figure: Cath O’Driscoll Nature Publishing 2004 Risk ID PGx Testing 1 People Respond Differently to Drugs Pharmacogenetic Markers Identified by Genome-Wide Association Drug Adverse Drug Risk Allele Reaction (ADR) Abacavir Hypersensitivity HLA-B*5701 Flucloxacillin Hepatotoxicity Allopurinol Cutaneous ADR HLA-B*5801 Carbamazepine Stevens-Johnson HLA-B*1502 Syndrome Augmentin Hepatotoxicity DRB1*1501 Ximelagatran Hepatotoxicity DRB1*0701 Ticlopidine Hepatotoxicity HLA-A*3303 Average preclinical populations and human hepatocytes lack the diversity to detect incidence of adverse events that occur only in 1/10,000 people. Current Rodent Models of Risk Assessment The Challenge “At a time of extraordinary scientific progress, methods have hardly changed in several decades ([FDA] 2004)… Toxicologists face a major challenge in the twenty-first century. They need to embrace the new “omics” techniques and ensure that they are using the most appropriate animals if their discipline is to become a more effective tool in drug development.” -Dr. Michael Festing Quantitative geneticist Toxicol Pathol. 2010;38(5):681-90 Rodent Models as a Strategy for Hazard Characterization and Pharmacogenetics Genetically defined rodent models may provide ability to: 1. Improve preclinical prediction of drugs that carry a human safety risk 2.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • ARID1B Is a Specific Vulnerability in ARID1A-Mutant Cancers The
    ARID1B is a specific vulnerability in ARID1A-mutant cancers The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Helming, K. C., X. Wang, B. G. Wilson, F. Vazquez, J. R. Haswell, H. E. Manchester, Y. Kim, et al. 2014. “ARID1B is a specific vulnerability in ARID1A-mutant cancers.” Nature medicine 20 (3): 251-254. doi:10.1038/nm.3480. http://dx.doi.org/10.1038/nm.3480. Published Version doi:10.1038/nm.3480 Accessed February 16, 2015 10:04:32 PM EST Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987227 Terms of Use This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA (Article begins on next page) NIH Public Access Author Manuscript Nat Med. Author manuscript; available in PMC 2014 September 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nat Med. 2014 March ; 20(3): 251–254. doi:10.1038/nm.3480. ARID1B is a specific vulnerability in ARID1A-mutant cancers Katherine C. Helming1,2,3,4,*, Xiaofeng Wang1,2,3,*, Boris G. Wilson1,2,3, Francisca Vazquez5, Jeffrey R. Haswell1,2,3, Haley E. Manchester1,2,3, Youngha Kim1,2,3, Gregory V. Kryukov5, Mahmoud Ghandi5, Andrew J. Aguirre5,6,7, Zainab Jagani8, Zhong Wang9, Levi A. Garraway6, William C. Hahn6,7, and Charles W.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Viewed in [2, 3])
    Yildiz et al. Neural Development (2019) 14:5 https://doi.org/10.1186/s13064-019-0129-x RESEARCH ARTICLE Open Access Zebrafish prdm12b acts independently of nkx6.1 repression to promote eng1b expression in the neural tube p1 domain Ozge Yildiz1, Gerald B. Downes2 and Charles G. Sagerström1* Abstract Background: Functioning of the adult nervous system depends on the establishment of neural circuits during embryogenesis. In vertebrates, neurons that make up motor circuits form in distinct domains along the dorsoventral axis of the neural tube. Each domain is characterized by a unique combination of transcription factors (TFs) that promote a specific fate, while repressing fates of adjacent domains. The prdm12 TF is required for the expression of eng1b and the generation of V1 interneurons in the p1 domain, but the details of its function remain unclear. Methods: We used CRISPR/Cas9 to generate the first germline mutants for prdm12 and employed this resource, together with classical luciferase reporter assays and co-immunoprecipitation experiments, to study prdm12b function in zebrafish. We also generated germline mutants for bhlhe22 and nkx6.1 to examine how these TFs act with prdm12b to control p1 formation. Results: We find that prdm12b mutants lack eng1b expression in the p1 domain and also possess an abnormal touch-evoked escape response. Using luciferase reporter assays, we demonstrate that Prdm12b acts as a transcriptional repressor. We also show that the Bhlhe22 TF binds via the Prdm12b zinc finger domain to form a complex. However, bhlhe22 mutants display normal eng1b expression in the p1 domain. While prdm12 has been proposed to promote p1 fates by repressing expression of the nkx6.1 TF, we do not observe an expansion of the nkx6.1 domain upon loss of prdm12b function, nor is eng1b expression restored upon simultaneous loss of prdm12b and nkx6.1.
    [Show full text]
  • A Flexible Microfluidic System for Single-Cell Transcriptome Profiling
    www.nature.com/scientificreports OPEN A fexible microfuidic system for single‑cell transcriptome profling elucidates phased transcriptional regulators of cell cycle Karen Davey1,7, Daniel Wong2,7, Filip Konopacki2, Eugene Kwa1, Tony Ly3, Heike Fiegler2 & Christopher R. Sibley 1,4,5,6* Single cell transcriptome profling has emerged as a breakthrough technology for the high‑resolution understanding of complex cellular systems. Here we report a fexible, cost‑efective and user‑ friendly droplet‑based microfuidics system, called the Nadia Instrument, that can allow 3′ mRNA capture of ~ 50,000 single cells or individual nuclei in a single run. The precise pressure‑based system demonstrates highly reproducible droplet size, low doublet rates and high mRNA capture efciencies that compare favorably in the feld. Moreover, when combined with the Nadia Innovate, the system can be transformed into an adaptable setup that enables use of diferent bufers and barcoded bead confgurations to facilitate diverse applications. Finally, by 3′ mRNA profling asynchronous human and mouse cells at diferent phases of the cell cycle, we demonstrate the system’s ability to readily distinguish distinct cell populations and infer underlying transcriptional regulatory networks. Notably this provided supportive evidence for multiple transcription factors that had little or no known link to the cell cycle (e.g. DRAP1, ZKSCAN1 and CEBPZ). In summary, the Nadia platform represents a promising and fexible technology for future transcriptomic studies, and other related applications, at cell resolution. Single cell transcriptome profling has recently emerged as a breakthrough technology for understanding how cellular heterogeneity contributes to complex biological systems. Indeed, cultured cells, microorganisms, biopsies, blood and other tissues can be rapidly profled for quantifcation of gene expression at cell resolution.
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • Hepatitis C Virus As a Unique Human Model Disease to Define
    viruses Review Hepatitis C Virus as a Unique Human Model Disease to Define Differences in the Transcriptional Landscape of T Cells in Acute versus Chronic Infection David Wolski and Georg M. Lauer * Liver Center at the Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA * Correspondence: [email protected]; Tel.: +1-617-724-7515 Received: 27 June 2019; Accepted: 23 July 2019; Published: 26 July 2019 Abstract: The hepatitis C virus is unique among chronic viral infections in that an acute outcome with complete viral elimination is observed in a minority of infected patients. This unique feature allows direct comparison of successful immune responses with those that fail in the setting of the same human infection. Here we review how this scenario can be used to achieve better understanding of transcriptional regulation of T-cell differentiation. Specifically, we discuss results from a study comparing transcriptional profiles of hepatitis C virus (HCV)-specific CD8 T-cells during early HCV infection between patients that do and do not control and eliminate HCV. Identification of early gene expression differences in key T-cell differentiation molecules as well as clearly distinct transcriptional networks related to cell metabolism and nucleosomal regulation reveal novel insights into the development of exhausted and memory T-cells. With additional transcriptional studies of HCV-specific CD4 and CD8 T-cells in different stages of infection currently underway, we expect HCV infection to become a valuable model disease to study human immunity to viruses. Keywords: viral hepatitis; hepatitis C virus; T cells; transcriptional regulation; transcription factors; metabolism; nucleosome 1.
    [Show full text]
  • The Genetic Basis of Hepatosplenic T-Cell Lymphoma
    Published OnlineFirst January 25, 2017; DOI: 10.1158/2159-8290.CD-16-0330 RESEARCH BRIEF The Genetic Basis of Hepatosplenic T-cell Lymphoma Matthew McKinney 1 , Andrea B. Moffi tt 2 , Philippe Gaulard 3 , Marion Travert 3 , Laurence De Leval4 , Alina Nicolae 5 , Mark Raffeld 5 , Elaine S. Jaffe 5 , Stefania Pittaluga 5 , Liqiang Xi 5 , Tayla Heavican 6 , Javeed Iqbal 6 , Karim Belhadj 3 , Marie Helene Delfau-Larue 3 , Virginie Fataccioli 3 , Magdalena B. Czader7 , Izidore S. Lossos 8 , Jennifer R. Chapman-Fredricks 8 , Kristy L. Richards 9 , Yuri Fedoriw 9 , Sarah L. Ondrejka10 , Eric D. Hsi 10 , Lawrence Low 11 , Dennis Weisenburger 11 , Wing C. Chan 11 , Neha Mehta-Shah12 , Steven Horwitz 12 , Leon Bernal-Mizrachi 13 , Christopher R. Flowers 13 , Anne W. Beaven 1 , Mayur Parihar 14 , Lucile Baseggio 15 , Marie Parrens 16 , Anne Moreau 17 , Pierre Sujobert 18 , Monika Pilichowska 19 , Andrew M. Evens 19 , Amy Chadburn 20 , Rex K.H. Au-Yeung 21 , Gopesh Srivastava 21 , William W. L. Choi 21 , John R. Goodlad 22 , Igor Aurer 23 , Sandra Basic-Kinda 23 , Randy D. Gascoyne 24 , Nicholas S. Davis 1 , Guojie Li 1 , Jenny Zhang 1 , Deepthi Rajagopalan 1 , Anupama Reddy 1 , Cassandra Love 1 , Shawn Levy 25 , Yuan Zhuang 1 , Jyotishka Datta 26 , David B. Dunson 26 , and Sandeep S. Davé 1 , 2 ABSTRACT Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing of 68 HSTLs, we defi ne recurrently mutated driver genes and copy-number alterations in the disease.
    [Show full text]
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]